Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | PGK2 | P07205 | 1/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | TPI1 | P60174 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PGD | P52209 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17243705 | 0.83 | SAT1 (0.33) | MAPK1LMNA | |
| SCHEMBL9943506 | 0.79 | PLA2G2A (0.31) | — | |
| SCHEMBL2513481 | 0.78 | LPAR3 (0.45) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL533763 | 0.74 | FDPS (0.44) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL16072566 | 0.73 | TSHR (0.31) | — | |
| SCHEMBL28770806 | 0.72 | TPI1 (0.42) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL29216424 | 0.72 | TPI1 (0.42) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| Water SCHEMBL27700129 | 0.72 | TPI1 (0.42) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| Phosphoric Acid SCHEMBL28705667 | 0.72 | TPI1 (0.42) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL28107423 | 0.72 | TPI1 (0.42) | LPAR3LPAR2LPAR1PGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1964843-B1 | PROCESS FOR PRODUCTION OF WATER-SOLUBLE AZOLE PRODRUG | EISAI R&D MAN CO LTD (JP) | 2013-08-28 | — | — | EP | disclosed |
| US-7803949-B2 | Process for preparation of water-soluble azole prodrugs | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7763649-B2 | Carotenoid analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763649-B2 | Carotenoid analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7592449-B2 | Structural carotenoid analogs for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090192316-A1 | PROCESS FOR PREPARATION OF WATER-SOLUBLE AZOLE PRODRUGS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-1964843-A1 | PROCESS FOR PRODUCTION OF WATER-SOLUBLE AZOLE PRODRUG | Eisai R&D Management Co., Ltd. (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-7320997-B2 | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320997-B2 | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192316-A1 | PROCESS FOR PREPARATION OF WATER-SOLUBLE AZOLE PRODRUGS | CYP3A5, CYP3A7, SLC19A1 | LPAR3 3112/4885LPAR2 3553/4885LPAR1 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.